The Progress of Diabetes Mellitus After HMS5552 Treatment in Type 2 Diabetes Mellitus

Majianhua

Status: Unknown

Conditions: Type2 Diabetes Mellitus

Treatments: Drug: HMS5552

Study type: Observational

Funder types: Other

Identifiers

NCT04091854

KY20190530-01-KS-01

Details and patient eligibility

About

At present, there are few studies on the clinical remission rate of diabetes after one year discontinuation of oral hypoglycemic drugs after intensive treatment. HMS5552 is a kind of GKA hypoglycemic drug. This study intends to observe the clinical remission rate of diabetes mellitus, beta cell function and blood sugar fluctuation of patients with type 2 diabetes mellitus who have been treated with HMS5552 for 52W or 28W and whose glucose control is up to the standard.

Enrollment: 24 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Complete HMS5552 treatment and safety visit;
• HbA1c < 8.0% was detected in our laboratory;
• Researchers judged the stability of glucose control based on the data of subjects'visits during HMS5552 treatment and the indicators of our hospital;
• Subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise;
• Willing to sign written informed consent and abide by the research program.

Exclusion criteria

• There was a state of illness in the subjects who could not complete the follow-up during the observation period.
• The researchers judged that subjects'compliance with HMS5552 was affected during treatment.

Trial design

24 participants in 1 patient group

HMS5552 treatment

Treatment:

Drug: HMS5552